195
Participants
Start Date
July 31, 2013
Primary Completion Date
March 18, 2016
Study Completion Date
December 8, 2017
HMA
azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
SGN-CD33A
Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
Memorial Sloan Kettering Cancer Center, New York
Winship Cancer Institute / Emory University School of Medicine, Atlanta
H. Lee Moffitt Cancer Center & Research Institute, Tampa
University of Alabama at Birmingham, Birmingham
Cleveland Clinic, The, Cleveland
University of Michigan Comprehensive Cancer Center, Ann Arbor
Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas
University of Utah, Salt Lake City
City of Hope National Medical Center, Duarte
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
MD Anderson Cancer Center / University of Texas, Houston
Fred Hutchinson Cancer Research Center, Seattle
Seagen Inc.
INDUSTRY